Virulence and disease in leishmaniasis: What is relevant for the patient?

Trends in Parasitology

Volumn 20, Issue 7, 2004, Pages 297-301

  Rivas, Luis ^a   Moreno, Javier ^b   Cañavate, Carmen ^b   Alvar, Jorge ^b  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; COMORBIDITY; DISEASE SEVERITY; HOST PARASITE INTERACTION; HOUSEKEEPING GENE; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INTRASPECIFIC VARIATION; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS; MOLECULAR CLONING; MORPHOLOGICAL TRAIT; PARASITE INCIDENCE; PARASITE LOCALIZATION; PARASITE SURVIVAL; PARASITE TRANSMISSION; PARASITE VIRULENCE; PATHOGENICITY; PHENOTYPIC VARIATION; PSYCHODIDAE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; VIRUS PATHOGENESIS;

LEISHMANIA INFANTUM; LEISHMANIA MAJOR; PROTOZOA; PSYCHODIDAE;

EID: 2942576123     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2004.05.005     Document Type: Short Survey

References (37)

1. Chang K.P., et al. Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop. 85:2003;375-390
2. Nelson K.E. Epidemiology of infectious diseases: general principles. Nelson K.E., et al. Infectious Disease Epidemiology, Theory and Practice. 2001;17-49 Aspen Publishers Inc
3. Casadevall A., Pirofski L.A. Host-pathogen interactions: the attributes of virulence. J. Infect. Dis. 184:2001;337-344
4. Poulin R., Combes C. The concept virulence: interpretations and implications. Parasitol. Today. 15:1999;474-475
5. Buates S., Matlashewski G. General suppression of macrophage gene expression during Leishmania donovani infection. J. Immunol. 166:2001;3416-3422
6. Marty P., et al. Leishmanin reaction in the human population of a highly endemic focus of canine leishmaniasis in Alpes-Maritimes, France. Trans. R. Soc. Trop. Med. Hyg. 86:1992;249-250
7. Badaró R., et al. New perspectives on a subclinical form of visceral leishmaniasis. J. Infect. Dis. 154:1986;1003-1011
8. World Health Organization (1995) Report on the consultative meeting on Leishmania/HIV co-infections, Rome, 6-7 September 1994. Document WHO/LEISH/95.35, Geneva, WHO.
9. López-Vélez R., et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am. J. Trop. Med. Hyg. 58:1998;436-443
10. Cruz I., et al. Leishmania in discarded syringes from intravenous drug users. Lancet. 359:2002;1124-1125
11. Desjeux P., et al. Leishmania/HIV co-infections: epidemiology in Europe. Ann. Trop. Med. Parasitol. 97:(Suppl. 1):2003;3-15
12. Molina R., et al. HIV and the transmission of Leishmania. Ann. Trop. Med. Parasitol. 97:(Suppl. 1):2003;29-45
13. Chicharro C., et al. Lower trypanosomatids in HIV/AIDS patients. Ann. Trop. Med. Parasitol. 97:(Suppl. 1):2003;75-78
14. Guerbouj S., et al. Gp63 polymorphism and population structure of Leishmania donovani complex: influence of the host selection pressure? Parasitology. 122:2001;25-35
15. Chicharro C., et al. Molecular epidemiology of Leishmania infantum on the island of Majorca: a comparison of phenotypic and genotypic tools. Trans. R. Soc. Trop. Med. Hyg. 96:(Suppl. 1):2002;93-99
16. Hondowicz B., Scott P. Influence of parasite load on the ability of type 1 T cells to control Leishmania major infection. Infect. Immun. 70:2002;498-503
17. Murray H.W. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int. J. Infect. Dis. 4:2000;158-177
18. Laguna F., et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania study group. AIDS. 13:1999;1063-1069
19. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biol. Dis. 2:2003;14-24
20. Carter K.C., et al. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob. Agents Chemother. 47:2003;1529-1535
21. Ghosh S., et al. Role of superoxide dismutase in survival of Leishmania within the macrophage. Biochem. J. 369:2003;447-452
22. Cauchetier E., et al. Characterisation of atovaquone resistance in Leishmania infantum promastigotes. Int. J. Parasitol. 32:2002;1043-1051
23. Jiménez M.I., et al. Leishmania infantum is clonal in AIDS patients too: epidemiological implications. AIDS. 11:1997;569-573
24. Panton L.J., et al. A test for genetic exchange in mixed infections of Leishmania major in the sand fly Phlebotomus papatasi. J. Protozool. 38:1991;224-228
25. Cámara M., et al. Evidence from genotypic and phenotypic markers that an attenuated line outgrows a virulent one in a mixed population of Leishmania major promastigotes cultured in vitro. Ann. Trop. Med. Parasitol. 89:1995;477-484
26. Garin Y.J., et al. Virulence of Leishmania infantum is expressed as a clonal and dominant phenotype in experimental infections. Infect. Immun. 69:2001;7365-7373
27. Oliver A., et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 288:2000;1251-1254
28. Segovia M. Leishmania gene amplification: a mechanism of drug resistance. Ann. Trop. Med. Parasitol. 88:1994;123-130
29. Grondin K., et al. Co-amplification of the γ-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA. EMBO J. 16:1997;3057-3065
30. Singh A.K., et al. Gene amplification in amphotericin B-resistant Leishmania tarentolae. Exp. Parasitol. 99:2001;141-147
31. Guimond C., et al. Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res. 31:2003;5886-5896
32. Beverley S.M. Protozomics: trypanosomatid parasite genetics comes of age. Nat. Rev. Genet. 4:2003;11-19
33. Foreman-Wykert A.K., Miller J.F. Hypervirulence and pathogen fitness. Trends Microbiol. 11:2003;105-108
34. Cunningham M.L., et al. Regulation of differentiation to the infective stage of the protozoan parasite Leishmania major by tetrahydrobiopterin. Science. 292:2001;285-287
35. Laskay T., et al. Neutrophil granulocytes - Trojan horses for Leishmania major and other intracellular microbes? Trends Microbiol. 11:2003;210-214
36. Bogdan C., et al. Fibroblasts as host cells in latent leishmaniosis. J. Exp. Med. 191:2000;2121-2130
37. Rittig M.G., Bogdan C. Leishmania-host-cell interaction: complexities and alternative views. Parasitol. Today. 16:2000;292-297